

SUPPORTING INFORMATION

Selective, Nontoxic CB₂ Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer

Paula Morales,[†] Sandra Blasco-Benito,^{†,‡} Clara Andradas,^{†,‡} María Gómez-Cañas,[‡] Juana María Flores,[§] Pilar Goya,[†] Javier Fernández-Ruiz,[‡] Cristina Sánchez,^{†,*} Nadine Jagerovic^{†,*}

[†]Instituto de Química Médica, CSIC, Calle Juan de la Cierva 3, 28006 Madrid, Spain

[‡]Departamento de Bioquímica y Biología Molecular I, Facultad de Biología, and [§]Departamento de Medicina y Cirugía Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040 Madrid, Spain

[‡]Instituto de Investigación Hospital 12 de Octubre, Av Cordova s/n, 28041 Madrid, Spain

[‡]Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, CIBERNED, IRYCIS, Universidad Complutense de Madrid, 28040 Madrid, Spain

Table of Content: page S1, Figure S1.




Figure S1. Effect of compound **10** on the viability of different triple negative breast cancer cell lines. The indicated cell lines were treated with increasing concentrations of compound **10**. Cell viability was determined 48 h after treatment. Values are the mean \pm SE of three independent experiments performed in duplicate. Data were analyzed by one-way analysis of variance followed by the Student-Newman-Keuls test.